表紙：自己免疫疾患ドラッグデリバリーデバイスの世界市場 (2019-2030年)：製品タイプ・適応症・製造区分・国別

市場調査レポート

商品コード

968659

自己免疫疾患ドラッグデリバリーデバイスの世界市場 (2019-2030年)：製品タイプ・適応症・製造区分・国別

Global Autoimmune Disorder Drug Delivery Devices Market: Focus on Product Type, Indication, Manufacturing Type, Country Data (14 Countries), and Competitive Landscape - Analysis and Forecast, 2019-2030

出版日: 2020年10月29日 | 発行:

BIS Research Inc. | ページ情報: 英文 247 Pages | 納期: 即日から翌営業日

価格

PDF (1-3 User License)

USD 3,250 373,782円

レポートPDFを3名様までご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストが可能です。PDFの印刷は可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF and Excel (Global License)

USD 5,200 598,052円

レポートPDFを同一企業の全世界の方にご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストが可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。付属のExcelには、PDF内で使用されている数値データが含まれます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=115.01円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の自己免疫疾患ドラッグデリバリーデバイスの市場規模は予測期間中15.25％のCAGRで推移し、2030年には106億8650万米ドルの規模に成長すると予測されています。高齢者人口の増加、自己免疫疾患を含む慢性疾患の発症率の増加、自己注射システムへの需要の増加などの要因が同市場の成長を推進しています。また、デバイスのR&Dへの大規模投資、各種自己免疫疾患の臨床試験の増加などの要因も今後の市場成長を牽引する見通しです。

当レポートでは、世界の自己免疫疾患ドラッグデリバリーデバイスの市場を調査し、市場の定義と概要、新型コロナウイルス感染症 (COVID-19) およびその他の市場影響因子の分析、市場規模の推移・予測、用途・エンドユーザー・地域/主要国など各種区分別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

エグゼクティブサマリー

第1章技術の定義

第2章調査範囲

第3章調査手法

第4章市場概要

注射デバイスの発展の経緯・将来の展望
プレフィルドシリンジの製造・パッケージング上の課題
市場成長の可能性
価格設定・償還シナリオ
特許満了・バイオシミラーの参入の影響
COVID-19の影響

第5章産業分析

概要
法規制の枠組み
法規制の枠組み・政府イニシアチブ
北米：法的要件・枠組み
欧州：法的要件・枠組み
アジア太平洋：法的要件・枠組み

第6章特許動向

第7章市場力学

概要
影響分析
促進要因
抑制要因
市場機会

第8章市場分析・予測：適応症別

関節リウマチ
乾癬
多発性硬化症
炎症性腸疾患
全身性エリテマトーデス

第9章市場分析・予測：製品別

ペンインジェクター
自動インジェクター
プレフィルドシリンジ
バイアル

第10章市場分析・予測：製造区分別

社内製造
アウトソーシング製造

第11章市場分析・予測：地域・主要国別

概要
北米
- 米国
- カナダ
欧州
- ドイツ
- 英国
- フランス
- イタリア
- スペイン
- その他
アジア太平洋
- 中国
- 日本
- インド
- 韓国
- オーストラリア
- その他
ラテンアメリカ
- ブラジル
- メキシコ
- その他
その他の地域

第12章競合情勢

主な展開・戦略
市場シェア分析

第13章企業プロファイル

Amgen Inc.
AbbVie Inc.
Bayer AG
Biogen Inc.
Bristol-Myers Squibb Company
Eli Lilly & Company
F. Hoffmann-La Roche Ltd
GlaxoSmithKline plc
Johnson & Johnson Services, Inc.
Merck KGaA
Novartis AG
Sanofi S.A.
Teva Pharmaceutical Industries Ltd.
UCB Pharma SA.

図表

List of Figures

Figure 1: Global Prevalence of Rheumatoid Arthritis (1990-2017)
Figure 2: Global Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 3: Impact Analysis
Figure 4: Share of Key Developments and Strategies, (September 2017-September 2020)
Figure 5: Global Autoimmune Disorder Drug Delivery Devices Market (by Product), ($Million), 2019 and 2030
Figure 6: Global Autoimmune Disorder Drug Delivery Devices Market (by Indication), ($Million), 2019 and 2030
Figure 7: Global Autoimmune Disorder Drug Delivery Devices Market (by Manufacturing Type), ($Million), 2019 and 2030
Figure 8: Global Autoimmune Disorder Drug Delivery Devices Market (by Region), ($Million), 2019-2030
Figure 2.1: Global Autoimmune Disorders Drug Delivery Devices Market Segmentation
Figure 3.1: Global Autoimmune Disorder Drug Delivery Devices Market Methodology
Figure 3.2: Primary Research Methodology
Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
Figure 4.1: Key Milestones in History of Syringes
Figure 4.2: Advancements in Injectable Drug Delivery Technology
Figure 4.3: Global Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 5.1: Global Autoimmune Disorder Drug Delivery Devices Market: Regulatory Landscape
Figure 5.2: FDA 510(k) Approval Timeline
Figure 5.3: Health Canada Class II-Medical Device Approval Process
Figure 5.4: European Commission Class IIa-Medical Device Approval Process
Figure 5.5: National Medical Products Administration Class III-Medical Device Approval Process
Figure 5.6: Pharmaceutical and Medical Devices Agency (PMDA) Class II-Medical Device Approval Process
Figure 5.7: Central Drug Standard Control Organization (CDSCO) Class B-Medical Device Approval Process
Figure 6.1: Number of Patents Filed, Autoimmune Disorders Drug Delivery Devices, January 2017-December 2019
Figure 6.2: Patent Analysis (by IPC Code)
Figure 6.3: Patent Analysis (by Country)
Figure 6.4: Patent Analysis (by Company)
Figure 7.1: Impact Analysis
Figure 7.2: Global Prevalence of Rheumatoid Arthritis (1990-2017)
Figure 7.3: Technological Advancements in Pre-Filled Syringes Over Time
Figure 7.4: Global Geriatric Population (by Age)
Figure 7.5: Analysis of Origin of Drugs to Treat Autoimmune Disorders
Figure 7.6: Opportunity Areas for Injectable Drug Delivery Devices
Figure 8.1: Global Autoimmune Disorder Drug Delivery Devices Market, by Indication
Figure 8.2: Global Autoimmune Disorder Drug Delivery Devices Market (by Indication), ($Million), 2019 and 2030
Figure 8.3: Global Autoimmune Disorder Drug Delivery Devices Market (by Rheumatoid Arthritis), ($Million), 2019-2030
Figure 8.4: Rheumatoid Arthritis Drug Delivery Devices Market (By Therapeutics), ($Million), 2017-2019
Figure 8.5: Global Autoimmune Disorder Drug Delivery Devices Market (by Psoriasis), ($Million), 2019-2030
Figure 8.6: Psoriasis Drug Delivery Devices Market (by Therapeutics), ($Million), 2017-2019
Figure 8.7: Global Autoimmune Disorder Drug Delivery Devices Market (by Multiple Sclerosis), ($Million), 2019-2030
Figure 8.8: Multiple Sclerosis Drug Delivery Devices Market (by Therapeutics), ($Million), 2017-2019
Figure 8.9: Global Autoimmune Disorder Drug Delivery Devices Market (by Inflammatory Bowel Diseases), ($Million), 2019-2030
Figure 8.10: Inflammatory Bowel Diseases Drug Delivery Devices Market (by Therapeutics), ($Million), 2017-2019
Figure 8.11: Global Autoimmune Disorder Drug Delivery Devices Market (Systemic Lupus Erythematosus), ($Million), 2019-2030
Figure 8.12: Systemic Lupus Erythematosus Drug Delivery Devices Market (by Therapeutics), ($Million), 2017-2019
Figure 9.1: Revenue Contribution of Different Products, 2019 and 2030
Figure 9.2: Global Autoimmune Disorder Drug Delivery Devices Market (Pen Injectors), ($Million), 2019-2030
Figure 9.3: Pen Injector based Autoimmune Disorder Drug Delivery Devices Market (by Therapeutics), ($Million), 2017-2019
Figure 9.4: Global Autoimmune Disorder Drug Delivery Devices Market (Auto-injectors), ($Million), 2019-2030
Figure 9.5: Auto-Injector based Autoimmune Disorder Drug Delivery Devices Market (by Therapeutics), ($Million), 2017-2019
Figure 9.6: Global Autoimmune Disorder Drug Delivery Devices Market (Pre-filled Syringes), ($Million), 2019-2030
Figure 9.7: Pre-filled Syringes based Autoimmune Disorder Drug Delivery Devices Market (by Therapeutics), ($Million), 2017-2019
Figure 9.8: Global Autoimmune Disorder Drug Delivery Devices Market (Vials), ($Million), 2019-2030
Figure 9.9: Vials based Autoimmune Disorder Drug Delivery Devices Market (by Therapeutics), ($Million), 2017-2019
Figure 10.1: Global Autoimmune Disorder Drug Delivery Devices Market (by Manufacturing Type), ($Million), 2019 and 2030
Figure 10.2: Global Autoimmune Disorder Drug Delivery Devices Market (by In-house Manufacturing), ($Million), 2019-2030
Figure 10.3: Global Autoimmune Disorder Drug Delivery Devices Market (by Outsourced Manufacturing), ($Million), 2019-2030
Figure 11.1: Global Autoimmune Disorder Drug Delivery Devices Market (by Region)
Figure 11.2: Global Autoimmune Disorder Drug Delivery Devices Market (by Region), ($Million), 2019-2030
Figure 11.3: North America Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 11.4: North America: Market Dynamics
Figure 11.5: Revenue Contributions of Different Countries in North America, ($Million), 2019 and 2030
Figure 11.6: U.S. Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 11.7: Canada Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 11.8: Europe Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 11.9: Europe: Market Dynamics
Figure 11.10: Revenue Contributions Different Countries in Europe, ($Million), 2019 and 2030
Figure 11.11: Germany Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 11.12: U.K. Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 11.13: France Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 11.14: Italy Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 11.15: Spain Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 11.16: Rest-of-Europe Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 11.17: Asia-Pacific Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 11.18: APAC: Market Dynamics
Figure 11.19: Revenue Contributions Different Countries in Asia-Pacific, ($Million), 2019 and 2030
Figure 11.20: China Autoimmune Disorder Drug Delivery Devices market, ($Million), 2019-2030
Figure 11.21: Japan Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 11.22: India Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 11.23: South Korea Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 11.24: Australia Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 11.25: RoAPAC Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 11.26: Latin America Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 11.27: Latin America: Market Dynamics
Figure 11.28: Revenue Contributions of Different Countries in Latin America, ($Million), 2019 and 2030
Figure 11.29: Brazil Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 11.30: Mexico Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 11.31: Rest-of-Latin America Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 11.32: RoW Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 12.1: Share of Key Developments and Strategies, September 2017-September 2020
Figure 12.2: Regulatory and Legal Developments Share (by Company), September 2017- September 2020
Figure 12.3: Partnerships, Alliances, and Business Expansions (by Company), September 2017-September 2020
Figure 12.4: Mergers and Acquisitions Share (by Company), September 2017-September 2020
Figure 12.5: Market Share Analysis (by Companies), 2018 and 2019
Figure 13.1: Total Number of Companies Profiled
Figure 13.2: Amgen Inc.: Overall Product Portfolio
Figure 13.3: Amgen Inc.: Overall Financials, 2017-2019
Figure 13.4: Amgen Inc.: Revenue (by Region), 2017-2019
Figure 13.5: Amgen Inc.: R&D Expenditure, 2017-2019
Figure 13.6: Amgen Inc.: SWOT Analysis
Figure 13.7: AbbVie Inc.: Overall Product Portfolio
Figure 13.8: AbbVie Inc.: Overall Financials, 2017-2019
Figure 13.9: AbbVie Inc.: Revenue (by Region), 2017-2019
Figure 13.10: AbbVie Inc.: R&D Expenditure, 2017-2019
Figure 13.11: AbbVie Inc.: SWOT Analysis
Figure 13.12: Bayer AG: Overall Product Portfolio
Figure 13.13: Bayer AG: Overall Financials, 2017-2019
Figure 13.14: Bayer AG: Revenue (by Segment), 2018-2019
Figure 13.15: Bayer AG: Revenue (by Region), 2017-2019
Figure 13.16: Bayer AG: R&D Expenditure, 2017-2019
Figure 13.17: Bayer AG: SWOT Analysis
Figure 13.18: Biogen Inc.: Overall Service Portfolio
Figure 13.19: Biogen Inc.: Overall Financials, 2017-2019
Figure 13.20: Biogen Inc.: Sales (by Product), 2017-2019
Figure 13.21: Biogen Inc.: Sales (by Region), 2017-2019
Figure 13.22: Biogen Inc.: R&D Expenditure, 2017-2019
Figure 13.23: Biogen Inc.: SWOT Analysis
Figure 13.24: Bristol Myers Squibb Company: Overall Product Portfolio
Figure 13.25: Bristol Myers Squibb Company: Overall Financials, 2017-2019
Figure 13.26: Bristol Myers Squibb Company: Revenue (by Region), 2017-2019
Figure 13.27: Bristol Myers Squibb Company: R&D Expenditure, 2017-2019
Figure 13.28: Bristol Myers Squibb Company: SWOT Analysis
Figure 13.29: Eli Lilly & Company: Product Portfolio
Figure 13.30: Eli Lilly & Company: Pipeline Product Portfolio
Figure 13.31: Eli Lilly & Company: Overall Financials, 2017-2019
Figure 13.32: Eli Lilly & Company: Revenue (by Region), 2017-2019
Figure 13.33: Key Insights About Financial Health of the Company
Figure 13.34: Eli Lilly & Company: SWOT Analysis
Figure 13.35: F. Hoffmann-La Roche Ltd: Product Portfolio
Figure 13.36: F. Hoffmann-La Roche Ltd: Overall Financials, 2017-2019
Figure 13.37: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2017-2019
Figure 13.38: F. Hoffmann-La Roche Ltd: Revenue (by Region), 2017-2019
Figure 13.39: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2017-2019
Figure 13.40: F. Hoffmann-La Roche Ltd: SWOT Analysis
Figure 13.41: GlaxoSmithKline plc: Pipeline Product Portfolio
Figure 13.42: GlaxoSmithKline plc: Overall Financials, 2017-2019
Figure 13.43: GlaxoSmithKline plc: Revenue (by Segment), 2017-2019
Figure 13.44: GlaxoSmithKline plc: Revenue (by Region), 2017-2019
Figure 13.45: GlaxoSmithKline plc: R&D Expenditure, 2017-2019
Figure 13.46: GlaxoSmithKline plc: SWOT Analysis
Figure 13.47: Johnson & Jonson Services, Inc.: Product Portfolio
Figure 13.48: Johnson & Jonson Services, Inc.: Pipeline Products Portfolio
Figure 13.49: Johnson & Johnson Services, Inc. Company: Overall Financials, 2017-2019
Figure 13.50: Johnson & Johnson Services, Inc. Company: R&D Expenditure, 2017-2019
Figure 13.51: Johnson & Johnson Services, Inc.: SWOT Analysis
Figure 13.52: Merck KGaA: Product Portfolio
Figure 13.53: Merck KGaA: Overall Financials, 2017-2019
Figure 13.54: Merck KGaA: Revenue (by Segment), 2017-2019
Figure 13.55: Merck KGaA: Revenue (by Region), 2017-2019
Figure 13.56: Merck KGaA: R&D Expenditure, 2017-2019
Figure 13.57: Merck KGaA: SWOT Analysis
Figure 13.58: Novartis AG: Products Portfolio
Figure 13.59: Novartis AG: Pipeline Products Portfolio
Figure 13.60: Novartis AG: Overall Financials, 2017-2019
Figure 13.61: Novartis AG Net Revenue (by Business Segment), 2017-2019
Figure 13.62: Novartis AG: Net Revenue (by Region), 2017-2019
Figure 13.63: Novartis AG: R&D Expense, 2017-2019
Figure 13.64: Novartis AG: SWOT Analysis
Figure 13.65: Sanofi S.A.: Overall Product Portfolio
Figure 13.66: Sanofi S.A.: Overall Financials, 2017-2019
Figure 13.67: Sanofi S.A.: Revenue (by Segment), 2017-2019
Figure 13.68: Sanofi S.A.: Revenue (by Region), 2017-2019
Figure 13.69: Sanofi S.A.: R&D Expenditure, 2017-2019
Figure 13.70: Sanofi S.A.: SWOT Analysis
Figure 13.71: Teva Pharmaceutical Industries Ltd.: Overall Product Portfolio
Figure 13.72: Teva Pharmaceutical Industries Ltd.: Overall Financials, 2017-2019
Figure 13.73: Teva Pharmaceutical Industries Ltd.: Net Revenue (by Business Segment), 2017-2019
Figure 13.74: Teva Pharmaceutical Industries Ltd.: Research and Development Expense, 2017-2019
Figure 13.75: Teva Pharmaceutical Industries Ltd.: SWOT Analysis
Figure 13.76: UCB Pharma SA: Overall Product Portfolio
Figure 13.77: UCB Pharma SA: Overall Product Portfolio
Figure 13.78: UCB Pharma SA: Overall Financials, 2017-2019
Figure 13.79: UCB Pharma SA: Revenue (by Product), 2017-2019
Figure 13.80: UCB Pharma SA: Revenue (by Region), 2017-2019
Figure 13.81: UCB Pharma SA: R&D Expenditure, 2017-2019
Figure 13.82: UCB Pharma SA: SWOT Analysis

List of Tables

Table 1: Leading Players in Global Autoimmune Disorder Drug Delivery Devices Market
Table 4.1: Patent Expiry of Autoimmune Disorder Therapeutics
Table 5.1: Legal Requirements and Frameworks Across the Globe
Table 7.1: Deaths Due to Multiple Sclerosis in Key Countries, 2015-2017
Table 7.2: Filing Requirements for Pre-filled Syringes:
Table 7.3: Differentiation of an Injectable Therapeutic Throughout its Life Cycle:
Table 7.4: Alternative Drug Delivery Technologies:
Table 8.1: Global Autoimmune Disorder Therapeutics Sales, 2017-2019

Product Code: BHL0986SA

"Global Autoimmune Disorders Drug Delivery Devices Market to Reach $10,686.5 Million by 2030."

Market Report Coverage - Autoimmune Disorder Drug Delivery Devices

Market Segmentation

Indication - Systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, and psoriasis

Product Type - Pen injectors, auto-injectors, pre-filled syringes, and vials

Manufacturing Type - In-house manufacturing and outsourced manufacturing

Regional Segmentation

North America - U.S., Canada
Europe - Germany, France, Italy, U.K., Spain, and Rest-of-Europe
Asia-Pacific - China, Japan, India, South Korea, Australia, and Rest-of-APAC
Latin America - Brazil, Mexico, and Rest-of-the-Latin America
Rest-of-the-World

Growth Drivers

Increased Prevalence of Autoimmune Disorders

Technological Advancements in the Field of Pre-Filled Syringes

Rising Geriatric Population

Surge of Biosimilars and Biologics in the Pharmaceutical Market

Device Connectivity to Ease Competitive Pressure

Market Challenges

Strict Legal Requirements and Regulations

Alternative Drug Delivery Technology

Market Opportunities

Providing Injectable Drug Delivery Devices for Untapped Autoimmune Disorders

Opportunities of Personalizing Treatments in Autoimmune Diseases

Key Companies Profiled

AbbVie Inc., Amgen Inc., F. Hoffmann- La Roche Ltd., Novartis AG, GlaxoSmithKline Plc, Bristol Myers Squibb Company, Biogen Inc., Merck KGaA, Bayer AG, Johnson & Johnson Services Inc., Teva Pharmaceutical Industries Ltd., Eli Lily and Company, Sanofi S.A., UCB Inc., and Takeda Pharmaceutical Company Limited, among others

Key Questions Answered in this Report:

What are the various autoimmune disorders drug delivery devices available in the market?

What are emerging drug delivery devices for the treatment of autoimmune disorders?

How does the pipeline for global autoimmune disorders drug delivery devices market look like?

What is the current market size and future potential of these drug delivery devices?

What are the major market drivers, challenges, and opportunities in the global autoimmune disorders drug delivery devices market?

What is the patent landscape of this market?

What will be the impact of COVID-19 on this market?

What are the guidelines implemented by different government bodies to regulate the approval of autoimmune disorders drug delivery devices?

What are the key technological developments on which the current industry leaders are spending a major share of their research and development (R&D) investments?

Who are the leading players holding dominating shares in the global autoimmune disorders drug delivery devices market, currently?

What are the key strategies incorporated by the players of global autoimmune disorders drug delivery devices market, to sustain the competition and retain their supremacy?

What is the current revenue contribution of the global autoimmune disorders drug delivery devices market (by product type), and how would it evolve in the forecast period?

What is the current revenue contribution of the global autoimmune disorders drug delivery devices market (by indication), and how would it evolve in the forecast period?

What is the current revenue contribution of the global autoimmune disorders drug delivery devices market (by route of administration), and how would it evolve in the forecast period?

What is the current revenue contribution of the global autoimmune disorders drug delivery devices market (by usage type), and how would it evolve in the forecast period?

What is the current revenue contribution of the global autoimmune disorders drug delivery devices market (by therapeutics), and how would it evolve in the forecast period?

Which region is expected to contribute to the highest revenue of the global autoimmune disorders drug delivery devices market during the forecast period?

Market Overview

Healthcare experts have found the autoimmune disorders industry to be one of the most rapidly evolving markets. The global market for autoimmune disorder drug delivery devices is predicted to grow at a CAGR of 15.25% over the forecast period of 2020-2030. The market is driven by certain factors, including the increasing global geriatric population, increasing incidence of chronic diseases including autoimmune disorders, and rise in demand for self-injectable systems.

The market is favored by the development of autoimmune disorder drug delivery devices for several clinical areas such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, and psoriasis. The increase in the geriatric population and incurable autoimmune disorders across the globe are expected to translate into a significantly higher demand for autoimmune disorder drug delivery devices.

Furthermore, the companies are investing huge amounts in research and development of autoimmune disorder drug delivery devices. The clinical trial landscape of different autoimmune disorders has been on the rise in recent years, and this will drive the autoimmune disorder drug delivery devices market in the future.

Within the research report, the market is segmented based on indication, product type, manufacturing type, and region. Each of these segments covers the market's snapshot over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The exponential rise in the adoption of self-injection devices for the treatment of autoimmune disorders has created a buzz among companies to invest in the development of novel autoimmune disorder drug delivery devices. Due to the leading market products and intense market penetration, Amgen Inc. has been a pioneer in this field and has been a significant competitor in this market.

Several other companies, such as Novartis AG, F. Hoffmann- La Roche Ltd., and Bristol Myers Squibb Company, have launched drug delivery devices for autoimmune disorders.

Based on region, North America holds the largest share of the autoimmune disorder drug delivery devices market due to improved healthcare infrastructure, rise in per capita income, and availability of state-of-the-art research laboratories and institutions in the region. Apart from this, the Asia-Pacific region is anticipated to grow at a high CAGR during the forecast period.

Executive Summary

1 Technology Definition

1.1 Inclusion and Exclusion Criteria
- 1.1.1 Inclusions
- 1.1.2 Exclusions

2 Research Scope

2.1 Key Questions Answered in the Report

3 Research Methodology

3.1 Autoimmune Disorder Drug Delivery Devices Market: Research Methodology
3.2 Primary Data Sources
3.3 Secondary Data Sources
3.4 Market Estimation Model
3.5 Criteria for Company Profiling

4 Market Overview

4.1 Historic Overview and Future Scope of Injectable Drug Delivery Devices
4.2 Pre-Filled Syringes Manufacturing and Packaging Challenges
4.3 Global Autoimmune Disorder Drug Delivery Devices Market and Growth Potential, 2019-2030
4.4 Pricing and Reimbursement Scenario
4.5 Impact of Patent Expiry and Entry of Biosimilars on Autoimmune Disorder Drug Delivery Devices Market
4.6 Impact of COVID-19 on Autoimmune Disorder Drug Delivery Devices Market

5 Industry Insights

5.1 Overview
5.2 Legal Requirements and Frameworks Across the Globe
5.3 Regulatory Framework and Government Initiatives
5.4 Legal Requirements and Frameworks in North America
- 5.4.1 Food and Drug Administration (FDA)
- 5.4.2 Health Canada
5.5 Legal Requirements and Frameworks in Europe
- 5.5.1 European Union
5.6 Legal Requirements and Frameworks in Asia-Pacific
- 5.6.1 National Medical Products Administration (NMPA)
- 5.6.2 Pharmaceutical and Medical Device Agency (PMDA)
- 5.6.3 Central Drug Standard Control Organization (CDSCO)

6 Patent Landscape

6.1 Patent Analysis (by Drug Delivery Devices)
6.2 Patent Analysis (by IPC Code)
6.3 Patent Analysis (by Country)
6.4 Patent Analysis (by Company)

7 Market Dynamics

7.1 Overview
7.2 Impact Analysis
7.3 Drivers
- 7.3.1 Increased Prevalence of Autoimmune Disorders
- 7.3.2 Technological Advancements in the Field of Pre-Filled Syringes
- 7.3.3 Rising Geriatric Population
- 7.3.4 Surge of Biosimilars and Biologics in the Pharmaceutical Market
- 7.3.5 Device Connectivity to Ease Competitive Pressure
7.4 Restraints
- 7.4.1 Strict Legal Requirements and Regulations
- 7.4.2 Alternative Drug Delivery Technology
7.5 Opportunities
- 7.5.1 Providing Injectable Drug Delivery Devices for Untapped Autoimmune Disorders
- 7.5.2 Opportunities for Personalizing Treatments in Autoimmune Diseases

8 Global Autoimmune Disorder Drug Delivery Devices Market, (by Indication), $Million, 2019-2030

8.1 Rheumatoid Arthritis
8.2 Psoriasis
8.3 Multiple Sclerosis
8.4 Inflammatory Bowel Diseases
8.5 Systemic Lupus Erythematosus

9 Global Autoimmune Disorder Drug Delivery Devices Market, (by Product), $Million, 2019-2030

9.1 Introduction
9.2 Pen Injectors
9.3 Auto-Injectors
9.4 Pre-filled Syringes
9.5 Vials

10 Global Autoimmune Disorder Drug Delivery Devices Market, (by Manufacturing Type), $Million, 2019-2030

10.1 In-House Manufacturing
10.2 Outsourced Manufacturing

11 Global Autoimmune Disorder Drug Delivery Devices Market, (by Region), $Million, 2019-2030

11.1 Overview
11.2 North America
- 11.2.1 U.S.
- 11.2.2 Canada
11.3 Europe
- 11.3.1 Germany
- 11.3.2 U.K.
- 11.3.3 France
- 11.3.4 Italy
- 11.3.5 Spain
- 11.3.6 Rest-of-Europe
11.4 Asia-Pacific
- 11.4.1 China
- 11.4.2 Japan
- 11.4.3 India
- 11.4.4 South Korea
- 11.4.5 Australia
- 11.4.6 Rest-of-APAC
11.5 Latin America
- 11.5.1 Brazil
- 11.5.2 Mexico
- 11.5.3 Rest-of-Latin America
11.6 Rest-of-the-World

12 Competitive Landscape

12.1 Key Developments and Strategies
- 12.1.1 Regulatory and Legal Developments
- 12.1.2 Partnerships, Alliances, and Business Expansions
- 12.1.3 Mergers and Acquisitions
12.2 Market Share Analysis

13 Company Profiles

13.1 Overview
13.2 Amgen Inc.
- 13.2.1 Company Overview
- 13.2.2 Role of Amgen Inc. in Global Autoimmune Disorder Drug Delivery Devices Market
- 13.2.3 Financials
- 13.2.4 Key Insights about Financial Health of the Company
- 13.2.5 SWOT Analysis
13.3 AbbVie Inc.
- 13.3.1 Company Overview
- 13.3.2 Role of AbbVie Inc. in Global Autoimmune Disorder Drug Delivery Devices Market
- 13.3.3 Financials
- 13.3.4 Key Insights about Financial Health of the Company
- 13.3.5 SWOT Analysis
13.4 Bayer AG
- 13.4.1 Company Overview
- 13.4.2 Role of Bayer AG in Global Autoimmune Disorder Drug Delivery Devices Market
- 13.4.3 Financials
- 13.4.4 Key Insight about Financial Health of the Company
- 13.4.5 SWOT Analysis
13.5 Biogen Inc.
- 13.5.1 Company Overview
- 13.5.2 Role of Biogen Inc. in Global Autoimmune Disorder Drug Delivery Devices Market
- 13.5.3 Financials
- 13.5.4 Key Insights about Financial Health of the Company
- 13.5.5 SWOT Analysis
13.6 Bristol-Myers Squibb Company
- 13.6.1 Company Overview
- 13.6.2 Role of Bristol Myers Squibb Company in the Global Autoimmune Disorder Drug Delivery Devices Market
- 13.6.3 Financials
- 13.6.4 Key Insights About Financial Health of the Company
- 13.6.5 SWOT Analysis
13.7 Eli Lilly & Company
- 13.7.1 Company Overview
- 13.7.2 Role of Eli Lilly & Company in Global Autoimmune Disorder Drug Delivery Device Market
- 13.7.3 Financials
- 13.7.4 Key Insights About Financial Health of the Company
- 13.7.5 SWOT Analysis
13.8 F. Hoffmann-La Roche Ltd
- 13.8.1 Company Overview
- 13.8.2 Role of F. Hoffmann-La Roche Ltd. in Global Autoimmune Disorder Drug Delivery Devices Market
- 13.8.3 Financials
- 13.8.4 Key Insights About Financial Health of the Company
- 13.8.5 SWOT Analysis
13.9 GlaxoSmithKline plc
- 13.9.1 Company Overview
- 13.9.2 Role of GlaxoSmithKline plc in Global Autoimmune Disorder Drug Delivery Devices Market
- 13.9.3 Financials
- 13.9.4 Key Insights About Financial Health of the Company
- 13.9.5 SWOT Analysis
13.1 Johnson & Johnson Services, Inc.
- 13.10.1 Company Overview
- 13.10.2 Role of Johnson & Johnson Services, Inc. in Global Autoimmune Disorder Drug Delivery Devices Market
- 13.10.3 Financials
- 13.10.4 Key Insights About Financial Health of the Company
- 13.10.5 SWOT Analysis
13.11 Merck KGaA
- 13.11.1 Company Overview
- 13.11.2 Role of Merck KGaA in Global Autoimmune Disorder Drug Delivery Devices Market
- 13.11.3 Financials
- 13.11.4 Key Insights About Financial Health of the Company
- 13.11.5 SWOT Analysis
13.12 Novartis AG
- 13.12.1 Company overview
- 13.12.2 Role of Novartis AG in Global Autoimmune Disorder Drug Delivery Devices Market
- 13.12.3 Financials
- 13.12.4 Key Insights About Financial Health of the Company
- 13.12.5 SWOT Analysis
13.13 Sanofi S.A.
- 13.13.1 Company Overview
- 13.13.2 Role of Sanofi S.A. in Global Autoimmune Disorder Drug Delivery Devices Market
- 13.13.3 Financials
- 13.13.4 Key Insights About Financial Health of the Company
- 13.13.5 SWOT Analysis
13.14 Teva Pharmaceutical Industries Ltd.
- 13.14.1 Company Overview
- 13.14.2 Role of Teva Pharmaceutical Industries Ltd. in Global Autoimmune Disorder Drug Delivery Devices Market
- 13.14.3 Financials
- 13.14.4 Key Insight About Financial Health of the Company
- 13.14.5 SWOT Analysis
13.15 UCB Pharma SA.
- 13.15.1 Company Overview
- 13.15.2 Role of UCB Pharma SA in Global Autoimmune Disorder Drug Delivery Devices Market
- 13.15.3 Financials
- 13.15.4 Key Insight About Financial Health of the Company
- 13.15.5 SWOT Analysis